Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Tectonic Therapeutic, Inc.

Get SEC filing alerts via email and in your feed for Tectonic Therapeutic, Inc.

TECX

Tectonic Therapeutic, Inc.

About Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of biologic drugs targeting G protein-coupled receptors (GPCRs) using its proprietary GEODe® platform. The company focuses on therapeutic proteins and antibodies to address serious diseases with limited treatment options, including pulmonary hypertension and hereditary hemorrhagic telangiectasia. Its business model centers on advancing novel GPCR-targeted biologics through clinical development for underserved patient populations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Tectonic Therapeutic, Inc.

1
1
Tectonic Therapeutic, Inc. Tectonic Therapeutics Reports $25.2 Million Net Loss in Q1 2026, Increases R&D Expenses

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Tectonic Therapeutic, Inc. Tectonic Therapeutics Reports $74.2 Million Net Loss and Increased R&D Expenses in Latest 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Tectonic Therapeutic, Inc. Tectonic Therapeutics Reports $19M Net Loss in Q3 2025, Increases R&D Spending

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Tectonic Therapeutic, Inc. Tectonic Therapeutics Reports $19.98 Million Net Loss and Significant Capital Raise in Latest 10-Q

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Tectonic Therapeutic, Inc. Tectonic Therapeutics Reports $15.9 Million Net Loss in Q1 2025, Cash Reserves Increase to $306.2 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Tectonic Therapeutic, Inc. Tectonic Therapeutic Reports $58M Net Loss for Fiscal Year 2024 Following Merger

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Tectonic Therapeutic, Inc. Tectonic Therapeutic Reports Significant Financial Changes Following Merger, Anticipates Ongoing Expenses for Research and Development

Via official filing (AI summary) | over 1 year ago | 0 comments